Junevity develops siRNA therapeutics using its proprietary RESET platform to achieve cell reprogramming for age-related diseases. This platform leverages omics data and machine learning to safely reverse transcriptional damage associated with complex conditions. The company is currently focusing its therapeutic development pipeline on metabolic disease and neurodegeneration.
Funding
Funding not disclosed
Founders
Product
Problem
Metabolic diseases affect over one billion people globally and are a leading cause of death. Identifying effective therapeutic targets for these complex diseases is challenging due to the intricate interplay of genetic, environmental, and lifestyle factors. Current approaches often fail to address the upstream transcriptional regulators that drive disease progression.
Solution
Junevity is developing therapeutics aimed at reversing metabolic diseases by targeting upstream transcriptional regulators. The company's REWIND platform analyzes extensive transcriptional data and known pharmacological pathways to identify these key regulators. By focusing on these upstream targets, Junevity aims to develop therapies that can effectively reverse the course of metabolic diseases, similar to the effects of exercise. The REWIND platform leverages innovations in genomics, machine learning, CRISPR, and regulatory biology to discover novel drug targets.
Target Audience
Junevity's primary focus is on individuals affected by metabolic diseases and the healthcare providers who treat them.
Features
- REWIND discovery platform analyzes billions of transcriptional data points from human metabolic disease.
- Identifies novel drug targets in known pharmacological pathways.
- Focuses on upstream regulators of complex metabolic disease.
- Utilizes genomics, machine learning, CRISPR, and regulatory biology.